Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioma × NSC 366140 × Clear all
NCT00005976 2013-06-03

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡